Global Neutropenia Treatment Market 2017-2021

Gglobal neutropenia treatment market overview

Technavio’s market research report predicts that the global neutropenia treatment market will grow at a CAGR of above 4% during the forecast period. Novel therapies combined with growing cases of chemotherapy-induced neutropenia is one of the primary drivers for market growth. Novel products such as Taiho’s drugs, ZOSYN 2.25, ZOSYN 4.5, and ZOSYN 4.5 for I.V. infusion bag, are in the pipeline and have received marketing approval for the treatment of febrile neutropenia in Japan in 2015. These products are anticipated to revolutionize the global market and the initiatives of the key vendors to increase the awareness about these novel mechanisms among healthcare experts will also strength fuel its growth. Moreover, the novel drug delivery technique also improves patient convenience leading to better patient adherence thus driving the market growth. For instance, Amgen launched Neulasta Onpro kit, a novel drug delivery mechanism that allows self-administration of Neulasta. Furthermore, since cancer is the known cause for developing neutropenia, the increasing cases of chemotherapy for the treatment of cancer will be a growth driver for the neutropenia treatment market.

Get A Free Sample

One of the latest trends that will gain traction in the global neutropenia treatment market is the advent of small molecules. The development of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals, with immune-boosting effects, is foreseen to revolutionize the therapeutic regimen for neutropenia. Along with immune-boosting effects, the Phase II trials have disclosed the anti-cancer effects of this molecule with much more benefits. Currently, the neutropenia treatment market is observed to have a high demand for cost-effective drugs for the treatment. As a result, vendors are concentrating on the development of small molecules which have lower manufacturing costs than biologics. 

Competitive analysis and key vendors

The neutropenia treatment market is characterized by the presence of several vendors and the competition in the market is expected to grow higher with the introduction of biosimilars. One of the key vendors Amgen is currently dominating the market and accounts for almost 70-75% of the market share. The company focuses on the areas of high unmet medical needs and uses its biologics manufacturing expertise to develop solutions to improve health outcomes and make people’s lives better. Moreover, the company also discovers, develops, manufactures, and offers innovative human therapeutics. Neulasta and NEUPOGEN are some of the key products introduced by Amgen.

Key vendors in the market are:

• Amgen
• Novartis
• Teva Pharmaceutical

The other prominent vendors include Hospira and Pfizer.

Segmentation by drug class and analysis of the neutropenia treatment market

• Granulocyte -colony- stimulating factor (G-CSF)
• Antibiotics
• Antifungal drugs

During 2016, G-CSF dominated the drug class segment of the neutropenia treatment market and is expected to grow moderately over the next four years. The increased utilization of G-CSF agents in stimulating the production of granulocyte will be the major factor driving the growth of the segment.

Geographical segmentation and analysis of the neutropenia treatment market

• Americas
• APAC
• EMEA

In terms of geography, the Americas led the neutropenia treatment market during 2016 and is foreseen to continue the domination during the forecast period. Factors such as the growing demand for therapeutic needs for febrile neutropenia in North America and the implementation of new legislation for the development and commercialization of biosimilars, will drive the growth of the market in this region.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global neutropenia treatment market?
• What are the key market trends impacting the growth of the global neutropenia treatment market?
• What are the challenges to market growth?
• Who are the key vendors in the global neutropenia treatment market?
• What are the market opportunities and threats faced by the vendors in the global neutropenia treatment market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global neutropenia treatment market?

Technavio also offers customization on reports based on specific client requirement.